Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Q3 2025 value amounting to $1.0 million.

  • Ironwood Pharmaceuticals' Current Deferred Revenue changed N/A to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2024, which is 2244.27% down from last year.
  • Ironwood Pharmaceuticals' Current Deferred Revenue amounted to $1.0 million in Q3 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Current Deferred Revenue registered a high of $2.6 million during Q4 2023, and its lowest value of $978000.0 during Q2 2025.
  • For the 3-year period, Ironwood Pharmaceuticals' Current Deferred Revenue averaged around $1.7 million, with its median value being $1.8 million (2025).
  • Data for Ironwood Pharmaceuticals' Current Deferred Revenue shows a peak YoY increase of 2244.27% (in 2024) and a maximum YoY decrease of 2244.27% (in 2024) over the last 5 years.
  • Over the past 3 years, Ironwood Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $2.6 million in 2023, then dropped by 22.44% to $2.0 million in 2024, then crashed by 48.43% to $1.0 million in 2025.
  • Its Current Deferred Revenue stands at $1.0 million for Q3 2025, versus $978000.0 for Q2 2025 and $1.8 million for Q1 2025.